SCHEMBL1471963

SCHEMBL1471963

NS(=O)(=O)c1ccc(Oc2c(Cl)cccc2[N+](=O)[O-])cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
POLB P06746 1/20 0.60
APEX1 P27695 1/20 0.58
BCL2L1 Q07817 1/20 0.53
MCL1 Q07820 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
VCAM1 P19320 1/20 0.50
ALDH1A1 P00352 4/20 0.49
HTT P42858 1/20 0.49
SOS1 Q07889 3/20 0.47
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.43
CA2 P00918 5/20 0.43
CA12 O43570 4/20 0.43
CA1 P00915 4/20 0.43
CA9 Q16790 4/20 0.43
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020458 0.87 MAPT (0.61) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL7213711 0.86 MAPT (0.63) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL14071618 0.86 MAPT (0.63) MAPTPOLBAPEX1BCL2L1MCL1
Hydrochloric Acid SCHEMBL27729273 0.85 MAPT (0.62) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL9818964 0.84 MAPT (0.67) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL7168591 0.84 MAPT (0.67) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL7406297 0.83 MAPT (0.59) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL2326248 0.82 MAPT (0.64) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL13749241 0.81 MAPT (0.67) MAPTPOLBAPEX1BCL2L1MCL1
SCHEMBL13720687 0.79 MAPT (0.64) MAPTPOLBAPEX1BCL2L1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US claimed
EP-1651595-A2 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2006-05-03 EP claimed
WO-2005007621-A2 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-01-27 WO claimed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US claimed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A MAPT 1796/4885POLB 1812/4885APEX1 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.